GSK stock gains on USD 750 million blood cancer drug deal and analyst upgrades
Published on 09/15/2026 at 22:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
GSK plc stock (ISIN GB0009252882) traded near 1,858.5 pence on the London Stock Exchange on September 15, 2026 as investors reacted to a new oncology acquisition worth up to USD 750 million and fresh analyst upgrades on the shares. According to Reuters on September 15, 2026, the company agreed to buy a trispecific T cell-engager drug from China-based Chimagen Biosciences in a deal valued at up to USD 750 million for blood cancer treatment.
USD 750 million multiple myeloma deal lifts GSK stock
As Alliance News reported on September 15, 2026, GSK agreed to buy what it described as a potential best-in-class trispecific T cell-engager aimed at treating multiple myeloma from Chimagen Biosciences for up to USD 750 million, combining upfront, milestone and potential royalty payments. The asset is expected to enter phase 1 clinical trials in 2027, adding another targeted therapy candidate to GSK's oncology pipeline.
According to Zonebourse on September 15, 2026, GSK's London-listed shares were up about 0.3 percent to around 1,860 pence in morning trading, modestly outperforming the FTSE 100 index, after the announcement of the Chimagen transaction. The move came a day after GSK had reported positive lung cancer trial data for two drugs, which helped drive a roughly 4.6 percent gain in the share price on September 14, 2026.
Berenberg turns positive and lifts GSK price target
The oncology deal was accompanied by a notable shift in analyst sentiment. According to Zonebourse on September 15, 2026, Berenberg raised its recommendation on GSK from Hold to Buy and increased the price target from GBP 20.00 to GBP 22.00, implying roughly 24 percent upside versus the last closing price before the note was published. The bank highlighted the strength and improving visibility of GSK's pipeline, with the Chimagen multiple myeloma asset adding further depth in blood cancer.
A separate analyst overview from MarketBeat on September 15, 2026 notes that Berenberg Bank lifted its GSK price target from GBX 2,000 to GBX 2,200 while maintaining a Hold rating in that particular dataset, pointing to potential upside of about 18.4 percent from the stock's current level referenced in the report. MarketBeat also cites other houses such as Royal Bank of Canada with a GBX 1,975 target and Jefferies with a GBX 2,500 target, resulting in a consensus rating of Hold and an average price target around GBX 2,064.
Recent price performance and market metrics
GSK's share price has moved noticeably over the past two sessions. As a recent report on September 15, 2026 summarized, GSK stock closed at 1,854.5 pence on the London Stock Exchange on September 14, 2026, up 4.63 percent from the prior close of about 1,772 pence, after investors reacted to positive results from two lung cancer drugs. Price data from a UK stock portal for September 15, 2026 indicate an opening level near 1,800.0 pence and an intraday range between roughly 1,789.5 and 1,861.5 pence, with the shares trading slightly above the previous day's close as of the latest snapshot.
According to intraday data from a UK financial portal on September 15, 2026, the London quote for GSK stood around 1,859.7 pence with trading volume of about 1.49 million shares for the latest completed session and a one-day gain of just over 5 percent over the prior trading day within the mid August to mid September period. The stock price around 1,858.5 pence sits close to the recent high of approximately 1,861.5 pence seen in the same period and remains below typical broker price targets in the GBX 1,975 to 2,500 range cited in recent analyst notes.
Pipeline momentum and risk considerations
On the fundamentals side, the Chimagen agreement adds to GSK's already active oncology and immunology pipeline. As GuruFocus reported on September 15, 2026, GSK secured full global rights to Chimagen Biosciences' trispecific T cell-engager program targeting multiple myeloma in a deal valued at up to USD 750 million, reinforcing the company's strategy to expand in oncology and immunology. GuruFocus notes that GSK shares recently traded around USD 50.05 on the New York Stock Exchange on September 14, 2026, up 4.0 percent on the day and about 9.6 percent above an estimated fair value metric of USD 45.68, illustrating how the market is already pricing in part of the growth expectations tied to the pipeline.
For investors, one risk highlighted by valuation tools is that GSK stock may appear moderately overvalued on certain fair value models after the latest rally, even as dividend sustainability remains a key attraction according to the same analysis from GuruFocus. Analyst consensus compiled by MarketBeat on September 15, 2026 still points to an average Hold recommendation and an overall price target around GBX 2,064, suggesting the market remains cautious, balancing pipeline momentum against execution and regulatory risks inherent in oncology development.
GSK stock price level as of mid September 2026
GSK stock closed at 1,854.5 pence on the London Stock Exchange on September 14, 2026 and was quoted around 1,858.5 pence in London trading on September 15, 2026, representing a gain of about 4.6 percent over the prior close and leaving the shares below Berenberg's raised GBP 22.00 price target and the GBX 2,064 consensus price objective. With the oncology deal worth up to USD 750 million, positive lung cancer trial results and a mix of Hold and Buy ratings from major banks, the stock remains closely watched by investors weighing pipeline-driven growth prospects against valuation and clinical risk.
Key data on GSK stock
- Company: GSK plc
- ISIN: GB0009252882
- Ticker: GSK
- Trading venue: London Stock Exchange
- Price (as of September 15, 2026): 1,858.5 pence GBP
- Market capitalization: 75,000,000,000 GBP (as of September 15, 2026)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: FTSE 100
